Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BofA Securities 2021 Virtual Healthcare Conference. Management will engage in a fireside chat on May 11 at 8:45 a.m. PT. Interested parties can access the live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on the adaptive immune system, developing diagnostic and therapeutic products for diseases like cancer and autoimmune conditions. The company has three commercial products and a strong clinical pipeline aimed at personalized medicine.

SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, May 11^th at 8:45 a.m. Pacific Time / 11:45 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com 

FAQ

When is Adaptive Biotechnologies participating in the BofA Securities 2021 Virtual Healthcare Conference?

Adaptive Biotechnologies will participate on May 11, 2021, at 8:45 a.m. Pacific Time.

How can I access the webcast for Adaptive Biotechnologies' presentation?

The live and archived webcast can be accessed on the 'Investors' section of Adaptive Biotechnologies' website.

What does Adaptive Biotechnologies specialize in?

Adaptive Biotechnologies specializes in harnessing the adaptive immune system to develop diagnostic and therapeutic products.

What type of diseases does Adaptive Biotechnologies aim to address?

The company aims to address diseases such as cancer, autoimmune conditions, and infectious diseases.

What is the stock symbol for Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.